Study Summary
This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Children CD19+ Leukemia Non-Hodgkin lymphoma treatment.
Want to learn more about this trial?
Request More InfoInterventions
CD19-TriCAR-T/SILKBIOLOGICAL
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hunan Provincial People's Hospital | Changsha | Hunan | China |